Sacubitril/valsartan and short-term changes in the 6-minute walk test: A pilot study
Impacto
Scholar |
Otros documentos de la autoría: Beltrán, Paola; Palau, Patricia; Domínguez Mafé, Eloy; Faraudo, Mercedes; Núñez, Eduardo
Metadatos
Mostrar el registro completo del ítemcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/36080
comunitat-uji-handle3:10234/36082
comunitat-uji-handle4:
INVESTIGACIONEste recurso está restringido
https://doi.org/10.1016/j.ijcard.2017.10.074 |
Metadatos
Título
Sacubitril/valsartan and short-term changes in the 6-minute walk test: A pilot studyFecha de publicación
2018-02Editor
ElsevierCita bibliográfica
BELTRÁN, Paola, et al. Sacubitril/valsartan and short-term changes in the 6-minute walk test: A pilot study. International journal of cardiology, 2018, vol. 252, p. 136-139.Tipo de documento
info:eu-repo/semantics/articleVersión de la editorial
http://www.internationaljournalofcardiology.com/article/S0167-5273(17)34071-8/ab ...Versión
info:eu-repo/semantics/publishedVersionPalabras clave / Materias
Resumen
Background
Impaired exercise capacity is the most disabling symptom in patients with heart failure with reduced ejection fraction (HFrEF). Despite sacubitril/valsartan showing reduced long-term morbidity and mortality ... [+]
Background
Impaired exercise capacity is the most disabling symptom in patients with heart failure with reduced ejection fraction (HFrEF). Despite sacubitril/valsartan showing reduced long-term morbidity and mortality over enalapril in HFrEF, its effects on short-term functional capacity remain uncertain. We sought to evaluate the effects of sacubitril/valsartan on a 30-day six-minute walk test in eligible patients with HFrEF.
Methods and results
From November 1, 2016 to February 1, 2017, a total of 58 stable symptomatic patients with HFrEF were eligible for sacubitril/valsartan and underwent 6-MWT before and 30 days after initiation of sacubitril/valsartan therapy. A mixed-effects model for repeated-measures was used to analyze the changes.
Mean age was 70 ± 11 years. 72.4% males, 46.6% with ischemic heart disease, and 51.7% on NYHA functional class III were included. The mean (SD) values of baseline LVEF and 6MWT were 30 ± 7%, and 300 ± 89 m, respectively. The median (IQR) of NT-proBNP at baseline was 2701 pg/ml (1087–4200). Compared with baseline, the 6-MWT distance increased significantly at 30 days by 13.9% (+∆ = 41.8 m (33.4–50.2); p < 0.001).
Conclusions
In this pilot study, sacubitril/valsartan was associated with an improvement in exercise tolerance in symptomatic patients with HFrEF. [-]
Derechos de acceso
Copyright © 2018 Elsevier Inc. All rights reserved.
http://rightsstatements.org/vocab/InC/1.0/
info:eu-repo/semantics/restrictedAccess
http://rightsstatements.org/vocab/InC/1.0/
info:eu-repo/semantics/restrictedAccess
Aparece en las colecciones
- MED_Articles [667]